Arrowhead Pharmaceuticals (BMV:ARWR *) - Prezzo delle azioni, notizie e analisi

ARWR * Panoramica delle azioni

Develops medicines for the treatment of intractable diseases in the United States.

ARWR * analisi fondamentale
Punteggio fiocco di neve
Valutazione	1/6
Crescita futura	2/6
Prestazioni passate	0/6
Salute finanziaria	5/6
Dividendi	0/6

Premi

Si prevede che i ricavi cresceranno 25.5% all'anno

Analisi del rischio

Le azioni sono altamente illiquide

Importanti vendite da parte di insider negli ultimi 3 mesi

Attualmente non redditizio e non si prevede che diventerà redditizio nei prossimi 3 anni

Arrowhead Pharmaceuticals, Inc. Concorrenti

Genomma Lab Internacional. de

BMV:LAB B

Mex$24.3b

Catalyst Pharmaceuticals

NasdaqCM:CPRX

US$2.5b

Zai Lab

NasdaqGM:ZLAB

US$3.2b

SpringWorks Therapeutics

NasdaqGS:SWTX

US$2.2b

Storia dei prezzi e prestazioni

Riepilogo dei massimi storici, delle variazioni e dei cali di prezzo di tutti i tempi per Arrowhead Pharmaceuticals
Prezzi storici delle azioni
Prezzo attuale dell'azione	US$586.00
Massimo di 52 settimane	US$619.39
Minimo di 52 settimane	US$583.00
Beta	0.87
1Variazione di 1 mese	0%
Variazione a 3 mesi	0.51%
Variazione di 1 anno	-58.11%
3Variazione a 3 anni	-45.03%
Variazione a 5 anni	n/a
Variazione dall'IPO	-41.61%

Notizie e aggiornamenti recenti

Recent updates

Rendimenti per gli azionisti

	ARWR *	MX Biotechs	MX Mercato
7D	0%	0%	0%
1Y	-58.1%	0%	0%

Ritorno vs Industria: ARWR * ha avuto una performance inferiore rispetto al MX Biotechs che ha registrato un rendimento 9.1 % nell'ultimo anno.

Rendimento vs Mercato: ARWR * ha avuto una performance inferiore al mercato MX che ha registrato un rendimento 2.4 % nell'ultimo anno.

Volatilità dei prezzi

Is ARWR *'s price volatile compared to industry and market?
ARWR * volatility
ARWR * Average Weekly Movement	n/a
Biotechs Industry Average Movement	0%
Market Average Movement	0%
10% most volatile stocks in MX Market	0%
10% least volatile stocks in MX Market	0%

Prezzo delle azioni stabile: ARWR * non ha avuto una volatilità dei prezzi significativa negli ultimi 3 mesi.

Volatilità nel tempo: Dati insufficienti per determinare la variazione della volatilità di ARWR * nell'ultimo anno.

Informazioni sull'azienda

Fondato	I dipendenti	AMMINISTRATORE DELEGATO	Sito web
2003	397	Chris Anzalone	arrowheadpharma.com

Arrowhead Pharmaceuticals, Inc. Riepilogo dei fondamenti

Come si confrontano gli utili e i ricavi di Arrowhead Pharmaceuticals con la sua capitalizzazione di mercato?
ARWR * statistiche fondamentali
Capitalizzazione di mercato	Mex$50.88b
Guadagni(TTM)	-Mex$3.24b
Ricavi(TTM)	Mex$4.59b

11.1x

Rapporto P/S

-15.7x

Rapporto P/E

ARWR * è sopravvalutato?

Vedi Fair Value e analisi di valutazione

Guadagni e ricavi

Statistiche chiave sulla redditività dall'ultima relazione sugli utili (TTM)
ARWR * Conto economico (TTM)
Ricavi	US$256.21m
Costo del fatturato	US$0
Profitto lordo	US$256.21m
Altre spese	US$437.32m
Guadagni	-US$181.11m

Ultimi guadagni dichiarati

Jun 30, 2023

Prossima data di guadagno

n/a

Utile per azione (EPS)	-1.69
Margine lordo	100.00%
Margine di profitto netto	-70.69%
Rapporto debito/patrimonio netto	68.9%

Come si è comportato ARWR * nel lungo periodo?

Vedi performance storica e confronto

ARWR * Panoramica delle azioni

Premi

Analisi del rischio

Arrowhead Pharmaceuticals, Inc. Concorrenti

BMV:LAB B

Mex$24.3b

NasdaqCM:CPRX

US$2.5b

NasdaqGM:ZLAB

US$3.2b

NasdaqGS:SWTX

US$2.2b

Storia dei prezzi e prestazioni

Notizie e aggiornamenti recenti

Arrowhead Pharmaceuticals, Inc. Presents New Pivotal Phase 3 Data At ESC 2024 from PALISADE Study of Plozasiran in Patients with Familial Chylomicronemia Syndrome

Arrowhead Pharmaceuticals, Inc. to Advance Two New RNAi-Based Obesity Candidates, ARO-INHBE and ARO-ALK7, into Clinical Studies

Arrowhead Pharmaceuticals to Advance RNAi-Based Plozasiran into Phase 3 Capitan Cardiovascular Outcomes Trial

Arrowhead Pharmaceuticals, Inc. Reports Successful Topline Results for Plozasiran from the Pivotal Phase 3 Palisade Study in Patients with Familial Chylomicronemia Syndrome

Arrowhead Pharmaceuticals Presents New Clinical Data Showing ARO-RAGE Achieves High Level of Gene Knockdown in Patients with Asthma

Arrowhead Pharmaceuticals Initiates Phase 1/2a Study of ARO-CFB for Treatment of Complement Mediated Kidney Disease

Recent updates

Arrowhead Pharmaceuticals, Inc. Presents New Pivotal Phase 3 Data At ESC 2024 from PALISADE Study of Plozasiran in Patients with Familial Chylomicronemia Syndrome

Arrowhead Pharmaceuticals, Inc. to Advance Two New RNAi-Based Obesity Candidates, ARO-INHBE and ARO-ALK7, into Clinical Studies

Arrowhead Pharmaceuticals to Advance RNAi-Based Plozasiran into Phase 3 Capitan Cardiovascular Outcomes Trial

Arrowhead Pharmaceuticals, Inc. Reports Successful Topline Results for Plozasiran from the Pivotal Phase 3 Palisade Study in Patients with Familial Chylomicronemia Syndrome

Arrowhead Pharmaceuticals Presents New Clinical Data Showing ARO-RAGE Achieves High Level of Gene Knockdown in Patients with Asthma

Arrowhead Pharmaceuticals Initiates Phase 1/2a Study of ARO-CFB for Treatment of Complement Mediated Kidney Disease

Arrowhead Pharmaceuticals, Inc. Announces New Phase 2 Data of Plozasiran Published in JAMA Cardiology and Presented at American College of Cardiology 73rd Annual Scientific Session & Expo

Arrowhead Pharmaceuticals Initiates Phase 1/2a Study of ARO-DM1 for Treatment of Type 1 Myotonic Dystrophy

Arrowhead Pharmaceuticals, Inc., Annual General Meeting, Mar 14, 2024

Arrowhead Pharmaceuticals, Inc. Announces Leaving of Javier San Martin, M.D., as the Chief Medical Officer, Effective from February 1, 2024

Arrowhead Pharmaceuticals, Inc. Files for Regulatory Clearance to Initiate Phase 1/2a Study of ARO-DM1 for Type 1 Myotonic Dystrophy

Arrowhead Pharmaceuticals Inc. Presents New Phase 2 Data on Plozasiran and Zodasiran at AHA 2023

Insufficient new directors

Arrowhead Pharmaceuticals Files for Regulatory Clearance to Initiate A Phase 1 Study of Aro-Sod1

Insufficient new directors

Chairman of the Board recently sold Mex$525k worth of stock

Arrowhead Pharmaceuticals, Inc. Gains Full Rights to NASH Candidate ARO-PNPLA3 with Promising Phase 1 Results

First quarter 2023 earnings released: US$0.39 loss per share (vs US$0.60 loss in 1Q 2022)

Arrowhead Pharmaceuticals Initiates Phase 1/2a Study of ARO-Mmp7 for Treatment of Idiopathic Pulmonary Fibrosis

Arrowhead Pharmaceuticals, Inc., Annual General Meeting, Mar 16, 2023

Arrowhead Pharmaceuticals, Inc. (NasdaqGS:ARWR) acquired unknown majority stake in Visirna Therapeutics.

Arrowhead Pharmaceuticals Inc. and Takeda Pharmaceutical Company Limited Announce Topline Results from SEQUOIA Phase 2 Study of Fazirsiran in Patients with Alpha-1 Antitrypsin Deficiency-Associated Liver Disease

Insufficient new directors

Arrowhead Pharmaceuticals Inc. to Present Topline Data from the Phase 2 SEQUOIA Study Evaluating Fazirsiran and Describe Design for Planned Phase 3 Study

Full year 2022 earnings released: US$1.67 loss per share (vs US$1.36 loss in FY 2021)

No longer forecast to breakeven

Arrowhead Presents New Phase 2 Data At AHA 2022 on Cardiometabolic Pipeline

Arrowhead Pharmaceuticals to Present Interim Phase 2 Clinical Data At AHA 2022 on SHASTA-2 Study of ARO-APOC3 and Arches-2 Study of ARO-ANG3

Third quarter 2022 earnings released: US$0.68 loss per share (vs US$0.29 loss in 3Q 2021)

Arrowhead Pharmaceuticals, Inc. Appoints Patrick O’Brien as Chief Operating Officer

Arrowhead Pharmaceuticals Inc. Initiates Phase 1/2a Studies for Two Pulmonary Candidates ARO-MUC5AC and ARO-RAGE

Takeda and Arrowhead Announce Results from Phase 2 Study of Fazirsiran in Patients with Alpha-1 Antitrypsin Deficiency Published in New England Journal of Medicine

Rendimenti per gli azionisti

Volatilità dei prezzi

Informazioni sull'azienda

Arrowhead Pharmaceuticals, Inc. Riepilogo dei fondamenti

11.1x

-15.7x

Guadagni e ricavi